Sympathetic Ophthalmia

Overview and Terminology

Sympathetic ophthalmia is best classified as a bilateral granulomatous panuveitis that follows penetrating trauma or intraocular surgery to one eye, with epithelioid cells and lymphocytes infiltrating the uveal tract of both eyes. Penetrating ocular injury (or intraocular surgery) exposes normally sequestered ocular antigens to the immune system, triggering the autoimmune cascade that ultimately produces inflammation in the fellow eye.

The disease has its own dedicated terminology, which is frequently tested precisely because it's easy to mix up. The eye that sustains the initial penetrating trauma or surgery — the one that triggers the autoimmune response — is called the exciting eye. The initially uninjured fellow eye that subsequently develops inflammation is called the sympathizing eye, which is where the disease gets its name.

Immunopathogenesis

Sympathetic ophthalmia is driven primarily by CD4+ Th1 lymphocytes reacting against sequestered ocular antigens, producing a delayed-type hypersensitivity response with granuloma formation. Mechanistically, it is best characterized as a Type IV (delayed-type) hypersensitivity reaction, T-cell-mediated and directed against exposed ocular self-antigens once the eye's normal immune privilege has been breached by injury.

Retinal S-antigen (arrestin), along with interphotoreceptor retinoid-binding protein, is a proposed sequestered autoantigen that becomes exposed after ocular injury and is thought to drive the autoimmune response. Genetic susceptibility also plays a role: HLA-DR4 (specifically DRB1*04 alleles) has been linked to increased susceptibility to sympathetic ophthalmia, supporting a genetically influenced component to the autoimmune mechanism.

Histopathology

The characteristic histopathologic finding in sympathetic ophthalmia is the Dalen-Fuchs nodule — small aggregates of epithelioid histiocytes and altered retinal pigment epithelium (RPE) cells situated between the RPE and Bruch's membrane, considered pathognomonic for the disease. On fundus exam, Dalen-Fuchs nodules appear as small yellow-white subretinal lesions; they are also classically seen in Vogt-Koyanagi- Harada disease, a related but distinct entity.

A distinguishing histologic feature is that the granulomatous inflammatory infiltrate typically spares the choriocapillaris and the overlying photoreceptors — unlike many other uveitic entities, where these structures are directly involved. This choriocapillaris-sparing pattern is a useful discriminator on pathology.

Clinical Presentation

Sympathetic ophthalmia typically presents as bilateral granulomatous uveitis, often panuveitis, affecting both the exciting and sympathizing eyes after penetrating injury or intraocular surgery to one eye, with the fellow eye subsequently becoming involved.

Epidemiology, Timing, and Risk Factors

Sympathetic ophthalmia is rare, occurring in roughly 0.2% to 0.5% of penetrating ocular injuries and an even smaller fraction of intraocular surgeries — despite its severe potential consequences, it remains an uncommon event relative to the overall volume of open globe injuries and intraocular surgery performed.

Timing follows a fairly predictable pattern: approximately 90% of cases develop within one year of the inciting ocular injury. Onset can, rarely, occur decades later, and vigilance is warranted even soon after trauma — the shortest reported interval between injury and onset of sympathetic ophthalmia is as brief as five days.

At the time of the initial injury, prolapse or incarceration of uveal tissue within the wound is the factor most associated with increased risk of subsequent sympathetic ophthalmia. Prolonged antigen exposure to the immune system and delayed wound healing from incarcerated uveal tissue both raise the risk, compared to injuries without uveal prolapse.

Treatment and Prevention

The mainstay of long-term treatment for sympathetic ophthalmia is systemic corticosteroids, often combined with steroid-sparing immunosuppressive agents, to control the bilateral granulomatous inflammation and preserve vision.

Prevention is a more nuanced topic. In a severely injured eye with no useful vision, enucleation of the injured eye within approximately two weeks of trauma has been described as significantly reducing the risk of developing sympathetic ophthalmia. This does not eliminate the risk entirely, and the decision must be balanced carefully against the injured eye's actual visual potential — enucleation is not a routine or universal recommendation for every penetrating injury, but a preventive option specifically considered when an eye has no useful vision remaining.

Related Topics

Continue exploring Ocular Trauma: